TY - JOUR
T1 - Treatment performance measures affect clinical outcomes in patients with acute systolic heart failure
T2 - Report from the Korean Heart Failure Registry
AU - Youn, Young Jin
AU - Yoo, Byung Su
AU - Lee, Jun Won
AU - Kim, Jang Young
AU - Han, Seong Woo
AU - Jeon, Eun Seok
AU - Cho, Myeong Chan
AU - Kim, Jae Joong
AU - Kang, Seok Min
AU - Chae, Shung Chull
AU - Oh, Byung Hee
AU - Choi, Dong Ju
AU - Lee, Myung Mook
AU - Ryu, Kyu Hyung
PY - 2012
Y1 - 2012
N2 - Background: There is a paucity of data on the effects of adherence to treatment on outcomes for patients with acute heart failure (HF) in Korea. We used HF performance measures to evaluate overall adherence and whether this affects clinical outcomes. Methods and Results: Among 3,466 patients in the Korean Heart Failure Registry, 1,527 patients with left ventricular systolic dysfunction (LVSD) who survived hospitalization were evaluated. Modified validated performance measures were defined as follows: use at discharge of angiotensin-converting enzyme inhibitor (ACEI), angiotensinreceptor II blocker (ARB), β-blocker or aldosterone receptor antagonist. Adherence to performance measures were as follows: ACEI or ARB at discharge, 68.0%; β-blocker at discharge, 40.9%; aldosterone receptor antagonist at discharge, 37.5%. On multivariate analysis, adherence to the measure of ACEI or ARB use at discharge was significantly associated with mortality (odds ratio (OR), 0.344; 95% confidence interval (CI), 0.123-0.964), readmission (OR, 0.180; 95%CI, 0.062-0.522) and mortality/readmission (OR, 0.297; 95%CI, 0.125-0.707) at 60 days and that for β-blocker with mortality (OR, 0.337; 95%CI, 0.147-0.774) at 1 year. Conclusions: For patients with LVSD in Korea, adherence to treatment performance measures, including prescription of an ACEI/ARB and β-blocker use at discharge, is associated with improved clinical outcomes.
AB - Background: There is a paucity of data on the effects of adherence to treatment on outcomes for patients with acute heart failure (HF) in Korea. We used HF performance measures to evaluate overall adherence and whether this affects clinical outcomes. Methods and Results: Among 3,466 patients in the Korean Heart Failure Registry, 1,527 patients with left ventricular systolic dysfunction (LVSD) who survived hospitalization were evaluated. Modified validated performance measures were defined as follows: use at discharge of angiotensin-converting enzyme inhibitor (ACEI), angiotensinreceptor II blocker (ARB), β-blocker or aldosterone receptor antagonist. Adherence to performance measures were as follows: ACEI or ARB at discharge, 68.0%; β-blocker at discharge, 40.9%; aldosterone receptor antagonist at discharge, 37.5%. On multivariate analysis, adherence to the measure of ACEI or ARB use at discharge was significantly associated with mortality (odds ratio (OR), 0.344; 95% confidence interval (CI), 0.123-0.964), readmission (OR, 0.180; 95%CI, 0.062-0.522) and mortality/readmission (OR, 0.297; 95%CI, 0.125-0.707) at 60 days and that for β-blocker with mortality (OR, 0.337; 95%CI, 0.147-0.774) at 1 year. Conclusions: For patients with LVSD in Korea, adherence to treatment performance measures, including prescription of an ACEI/ARB and β-blocker use at discharge, is associated with improved clinical outcomes.
KW - Left ventricular systolic dysfunction
KW - Mortality
KW - Performance measures
UR - http://www.scopus.com/inward/record.url?scp=84860290579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860290579&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-11-1093
DO - 10.1253/circj.CJ-11-1093
M3 - Article
C2 - 22343195
AN - SCOPUS:84860290579
SN - 1346-9843
VL - 76
SP - 1151
EP - 1158
JO - Circulation Journal
JF - Circulation Journal
IS - 5
ER -